SCHEMBL6212976

SCHEMBL6212976

CCOc1ccccc1-c1nc2c3cnn(CCc4ccccc4)c3ncn2n1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 2/20 0.70
SMN1; SMN2 Q16637 5/20 0.49
NPC1 O15118 4/20 0.49
RAB9A P51151 4/20 0.49
ALDH1A1 P00352 4/20 0.49
TSHR P16473 1/20 0.49
ADORA1 P30542 2/20 0.45
TP53 P04637 6/20 0.44
MDM2 Q00987 5/20 0.44
SIGMAR1 Q99720 1/20 0.43
MAPT P10636 1/20 0.43
ADORA2A P29274 3/20 0.41
KDM4E B2RXH2 1/20 0.41
CYP3A4 P08684 1/20 0.41
HPGD P15428 1/20 0.41
ALOX15 P16050 1/20 0.41
MAPK1 P28482 1/20 0.41
ADORA2B P29275 1/20 0.41
HSD17B10 Q99714 1/20 0.41
MEN1 O00255 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5823566 0.83 ADORA3 (1.00) ADORA3SMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL29794081 0.78 ADORA1 (0.49) ADORA3SMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL6216600 0.78 ADORA2A (0.67) ADORA3SMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL4758529 0.77 ADORA2A (0.68) ADORA3SMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL29794056 0.76 ADORA2A (0.54) ADORA3SMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL30393625 0.75 NPC1 (0.63) ADORA3SMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL5821433 0.67 ADORA1 (0.78) ADORA3SMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL644506 0.66 SMN1; SMN2 (1.00) SMN1; SMN2NPC1RAB9AALDH1A1TSHR
SCHEMBL4760138 0.65 KDM4E (0.61) ADORA3SMN1; SMN2NPC1RAB9AALDH1A1
SCHEMBL11642264 0.65 ADORA3 (0.47) ADORA3SMN1; SMN2NPC1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1549319-A2 PHARMACEUTICALLY ACTIVE COMPOUNDS HAVING A TRICYCLIC PYRAZOLOTRIAZOLOPYRIMIDINE RING STRUCTURE AND METHODS OF USE King Pharmaceuticals Research and Development Inc. (US) 2005-07-06 EP disclosed
WO-2003101455-A2 PHARMACEUTICALLY ACTIVE COMPOUNDS HAVING A TRICYCLIC PYRAZOLOTRIAZOLOPYRIMIDINE RING STRUCTURE AND METHODS OF USE KING PHARMACEUTICALS RESEARCH & DEVELOPMENT, INC. (US) 2003-12-11 WO disclosed